Equities research analysts at StockNews.com started coverage on shares of Aptevo Therapeutics (NASDAQ:APVO – Get Rating) in a report issued on Friday. The firm set a “hold” rating on the biotechnology company’s stock.
Aptevo Therapeutics Stock Down 3.0 %
APVO stock opened at $1.63 on Friday. The firm’s 50-day simple moving average is $1.81 and its 200 day simple moving average is $2.22. Aptevo Therapeutics has a fifty-two week low of $1.53 and a fifty-two week high of $7.20.
Aptevo Therapeutics (NASDAQ:APVO – Get Rating) last announced its earnings results on Thursday, May 11th. The biotechnology company reported $0.26 EPS for the quarter, topping the consensus estimate of ($1.19) by $1.45. As a group, analysts forecast that Aptevo Therapeutics will post -3.24 EPS for the current fiscal year.
Institutional Trading of Aptevo Therapeutics
Aptevo Therapeutics Company Profile
Aptevo Therapeutics, Inc is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology.
- Get a free copy of the StockNews.com research report on Aptevo Therapeutics (APVO)
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
- Best Buy’s Comeback Is Still At Play, Earnings Call For Patience
- e.l.f. Beauty Has Giant Quarter, Shares Hit New High
- If You Can Only Pick One Stock For The Rest Of 2023, Pick Nvidia
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.